Article: Immune Response Bears Brunt of Partner's Pullout.(Agouron Pharmaceuticals will no longer fund development of its experimental HIV vaccine, Remune)(Brief Article)

Biotech: Stock Falls on News of Lost Funds for HIV Vaccine Development

CARLSBAD -- Immune Response Corp. barely announced the withdrawal of its development and marketing partner When it was hit with a class-action lawsuit.

On July 6, the Carlsbad company's shares fell $2.01 to $2.58 after the firm reported Pfizer Inc.'s San Diego-based Agouron Pharmaceuticals unit will no longer fund development of its experimental HIV vaccine, Remune.

On July 11, attorney Edward J. Carreiro of Hatboro, Pa., filed a lawsuit on behalf of shareholders against Immune Response.

Laura Hansen, a company spokeswoman, said company officials were in Argentina ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!